Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA EGFR+ NSCLC (Except with RB Alterations?) When Adopting Adjuvant Osimertinib

Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA EGFR+ NSCLC (Except with RB Alterations?) When Adopting Adjuvant Osimertinib

Shannon S Zhang,1 Sai-Hong Ignatius Ou1,2 1University of California Irvine School of Medicine, Department of Medicine, Orange, CA, USA; 2Chao Family Comprehensive Cancer Center, Orange, CA, USACorrespondence: Sai-Hong Ignatius Ou, University of California, Irvine School of Medicine, Department of Me...

Full description

Bibliographic Details
Main Authors: Zhang SS, Ou SI
Format: Article
Language:English
Published: Dove Medical Press 2022-04-01
Series:Lung Cancer: Targets and Therapy
Subjects:
adaura
osimertinib
egfr mutation
resected nsclc
adjuvant
platinum chemotherapy
cisplatin
Online Access:https://www.dovepress.com/deconstructing-adaura-it-is-time-to-forgo-adjuvant-platinum-based-chem-peer-reviewed-fulltext-article-LCTT

Internet

https://www.dovepress.com/deconstructing-adaura-it-is-time-to-forgo-adjuvant-platinum-based-chem-peer-reviewed-fulltext-article-LCTT

Similar Items